Biding your time buying is becoming costly
Companies with late-stage assets have been attracting ever higher price tags over the past five years, Evaluate Vantage finds.
Device makers buy big
Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Biotech investors pray for a takeover miracle
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
Covid-19 scrambles big medtech’s spending
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Biopharma needs a biggie to avoid a down deal year
M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
Why some Spac deals are not all they’re cracked up to be
While blank-cheque mergers can net healthtechs a huge amount of capital, not all investors stay the course.
